Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
Introduction: Myasthenia gravis (MG) is an antibody mediated autoimmune neuromuscular disorder characterized by fatigable muscle weakness. A proportion of myasthenia gravis patients are classified as refractory due to non responsiveness to conventional treatment. This retrospective study was done to...
Main Authors: | Sudulagunta, Sreenivasa Rao, Sepehrar, Mona, Sodalagunta, Mahesh Babu, Settikere Nataraju, Aravinda, Bangalore Raja, Shiva Kumar, Sathyanarayana, Deepak, Gummadi, Siddharth, Burra, Hemanth Kumar |
---|---|
Format: | Article |
Language: | deu |
Published: |
German Medical Science GMS Publishing House
2016-10-01
|
Series: | GMS German Medical Science |
Subjects: | |
Online Access: | http://www.egms.de/static/en/journals/gms/2016-14/000239.shtml |
Similar Items
-
Rituximab treatment in myasthenia gravis
by: Ana Vesperinas-Castro, et al.
Published: (2023-10-01) -
Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis
by: Cong Zhao, et al.
Published: (2021-10-01) -
Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
by: Ting LI, et al.
Published: (2020-01-01) -
Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
by: Meng X, et al.
Published: (2022-05-01) -
Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
by: Farzad Fatehi, et al.
Published: (2021-08-01)